Sanofi-GSK Covid-19 Booster Showing Strong Immune Response, Sanofi Says
13 Giugno 2022 - 8:43AM
Dow Jones News
By Maitane Sardon
Sanofi SA said Monday that the Covid-19 booster vaccine it is
developing with U.K. drug company GlaxoSmithKline has shown strong
immune response in vaccinated adults in a Phase 3 trial.
The French pharma company said the jointly produced
next-generation booster has potential to protect against multiple
variants, including Omicron BA.1 and BA.2.
The company also said that another trial has shown that, in
adults with two doses of the Pfizer-BioNTech Comirnaty vaccine, the
Sanofi-GSK booster generated a higher immune response than the
Pfizer-BioNTech's booster.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
June 13, 2022 02:28 ET (06:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024